Similar to PNPLA3 are TM6SF2, GCKR and MBOAT7 mutations which increase the odds of promoting NASH progression by 1.18 to 1.55 fold but are rarer compared to PNPLA3 [53-55]. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.